<DOC>
	<DOCNO>NCT00908921</DOCNO>
	<brief_summary>To investigate glycosylated hemoglobin ( HbA1c ) control Glimepiride ( AMARYL ) OAD initiation mono-therapy type 2 diabetic patient China .</brief_summary>
	<brief_title>Efficacy Safety Glimepiride Oral Anti-Diabetic ( OAD ) Initiation Mono-therapy Chinese Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Newly diagnose T2DM inadequately control diet exercise T2DM diagnose &lt; 6 month take oral antidiabetic medication insulin &gt; 3months . HbA1C 7.5 less 11 . Fasting plasma glucose &gt; 13.5mmol/L Type 1 Diabetes Mellitus ( T1DM ) Patient acute illness hospitalize last 2 month Patient active liver disease , impaired renal hepatic function Known hypersensitivity glimepiride , sulfonylurea , sulfonamide excipients AMARYL Pregnant lactate woman The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>